Latest Breaking News On - Bill lundberg - Page 1 : comparemela.com

Merus MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting | 03 06 24

Merus MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting | 03 06 24
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChicago mayAmerican society of clinical oncologyExchange commissionBetta pharmaceuticals coAnnual meetingBill lundbergChief executive officerHepatocyte growth factor receptorBetta pharmaceuticalsPrivate securities litigation reform actAnnual report

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 Merus N.V. , a clinical-stage oncology company developing innovative, full-length multispecific antibodies , today announced updated.

United kingdomUnited statesChicago mayAmerican society of clinical oncologyExchange commissionAnnual meetingBill lundbergChief executive officerSolid tumorsResponse evaluation criteriaPrivate securities litigation reform actAnnual report

Merus N V : Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®),

United kingdomXand linkedinBill lundbergChief executive officerJefferies global healthcare conferenceIhr portfolio

Merus N V : Merus Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024(Nasdaq: MRUS) (Merus, the Company

United statesUnited kingdomJerome fayetteCompany conference callExchange commissionAmerican society of clinical oncologyClinical oncologyAnnual meetingBill lundbergChief executive officerResponse evaluation criteriaSolid tumorsConference callToll freePrivate securities litigation reform actAnnual report

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAmerican society of clinical oncologyCompany conference callExchange commissionAnnual meetingBill lundbergChief executive officerTuesday mayResponse evaluation criteriaSolid tumorsConference callToll freePrivate securities litigation reform actAnnual report